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for mortality with respect to either culprit vessel (log-rank-p-val-
ue¼0.54) or proximal vs. mid/distal location of the culprit lesion
within the vessel (log-rank-p-value¼0.45). This was also true after
multivariable adjustment, independent predictors of outcome were
serum lactate, success of revascularization, age, serum creatinine,
prior stroke, known peripheral artery disease and left bundle branch
block in admission electrocardiogram.
CONCLUSIONS For patients with CS complicating myocardial infarction,
the culprit lesion localization seems to be unrelated with mortality.
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BACKGROUND The Glucagon Like Peptide 1 receptor agonist exena-
tide is an incretin based compound used for glycemic control in pa-
tients with type 2 diabetes mellitus (DM) and has previously been
demonstrated to have cardioprotective properties. This double blin-
ded, randomized clinical trial studies the effect of exenatide treat-
ment on myocardial salvage in ST Elevated Myocardial Infarction
(STEMI) patients who successfully underwent primary Percutaneous
Coronary Intervention (PCI).
METHODS STEMI patients were randomly assigned to either intrave-
nous exenatide or placebo. Study medication was started prior to PCI
using 10 mg/h for 30minutes followed by 0.84 mg/h for 72h. Patientswith
a previous STEMI, Thrombolysis In Myocardial Infarction ﬂow 2 of 3,
multi vessel disease, or DM were excluded. Magnetic resonance imag-
ing was performed within 2-7 days after PCI, to determine left ventric-
ular (LV) volumes and ejection fraction (EF), infarct size and area at risk
(using T2-weighted hyperintensity (T2W) and late enhancement
endocardial surface area (ESA)). The primary endpoint of myocardial
salvage index (MSI) was deﬁned as the difference between the area at
risk and total infarct size, as ratio of the area at risk. Secondary end-
points were major cardiovascular events ((MACE) deﬁned as cardiac
death, repeat STEMI, coronary artery bypass grafting or repeat PCI), LV
end systolic volume (ESV), LV EF and infarct size.
RESULTS In total 91 patients (age 57.4  10.1 years, 76% male)
completed the study. There were no baseline differences between
both groups. Symptom to balloon time was 18185 vs. 20195 min
(p¼0.24) for exenatide (n¼42) and placebo (n¼49) respectively. Pa-
tients receiving exenatide had signiﬁcantly more episodes of nausea
early after study drug initiation (16 vs 4 patients, p<0.001), but this
did not lead to study discontinuation and was treated successfully
with metoclopramide in all cases. The MSI was not signiﬁcantly
different between both groups (with ESA 0.30  0.26 vs 0.26  0.22,
p¼0.43 and with T2W 0.35  0.25 vs 0.33  0.22, p¼0.65 for exenatide
vs placebo respectively). There were also no differences in LV ESV
(61.3  26.0 vs 54.9  25.9 ml/m2, p¼0.259), LV EF (52.6  7.7 vs. 52.4
 6.9%, p¼0.53) and infarct size (18.8  13.2 vs. 18.8  11.3% of LV
mass, p¼0.965). No MACE occurred during the in-hospital phase.
CONCLUSIONS Our exenatide treatment protocol does not improve
myocardial salvage in STEMI patients successfully treated with pri-
mary PCI. This is incongruent with previous clinical trail results.
Differences in the exenatide treatment protocols are the most obvious
reason for the ambiguous trial results. Further studies are needed to
establish the exact role and the optimal treatment protocol of exe-
natide in this group of patients.
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BACKGROUND Limited information is available about the efﬁcacy
and outcomes after primary percutaneous coronary intervention (P-
PCI) in very elderly patients (pts) with ST Elevation Myocardial
Infarction (STEMI).
METHODS 23 nonagenarian pts were treated (1% of the total STEMI
population underwent P-PCI). We evaluated in-hospital, 6-months
and 1 year-mortality in a retrospective analysis of nonagenarian pts
admitted at our Department with STEMI and treated with P-PCI from
November 2004 and December 2013. A bivariate analysis was carried
on with exact Fisher’s test, identifying those variables associated with
mortality. Odds ratios (ORs) from univariate logistic regression ana-
lyses were performed.
RESULTS All pts received aspirin and 300 mg clopidogrel loading
dose. Mean age: 91.2 yrs (range 90-96). 65% was women. Mean left
ventricular ejection fraction (LVEF) at the admission: 38.9% (23% of
pts with LVEF<35%). Advanced Killip class (3-4) at presentation: 10
pts (43%). Baseline characteristic: 13% of pts with prior revasculari-
zation, 17.3% prior stroke, 21.7% diabetes, 43% hypertension, 8.6%
atrial ﬁbrillation. No dementia (good mental status). Mean renal
function evaluated by creatinine clearance measured by the Cock-
croft–Gault equation: 38.7 mL/min (range 16.8 – 72.9). Mean hemo-
globin value: 13.7 gr/dL. Mean number of vessels treated per pts: 1.04,
showing a strategy of treating the culprit vessel only. 3 left main (LM),
8 left anterior descending coronary artery (LAD), 4 circumﬂex coro-
nary artery, 8 right coronary artery (RCA). The radial approach was
performed in 65% (100% of cases from 2012). The proportion of radial
to femoral shift was 6%. An average of 1.26 stents per pt were
implanted (100% were bare metal stent). In 4 pts we performed P-PCI
without stent. No Glycoprotein IIb/IIIa were used. Intra-aortic balloon
pump was implanted in 1 pt. The TIMI ﬂow 2-3 post P-PCI was ach-
ieved in 78.2% of pts (angiographic success was achieved in 20/23 pts).
In 1 pt occurred acute renal failure post P-PCI and in 1 pt occurred
major bleeding; no stroke. The overall in-hospital mortality rate was
34.7% (one pt died during the procedure). Cumulative mortality after
discharge at 6 months was 14% and at 1 year was 28%. LVEF<30
showed a higher risk of in-hospital mortality and cumulative mortality
at 6 months. Killip3 showed a higher risk of in-hospital mortality. LM
and LAD showed a higher risk of in-hospital mortality, cumulative
mortality at 6 months and at 1 year.
CONCLUSIONS Our data suggest that primary P-PCI in nonagenarian
pts can be performed with an acceptable bleeding risk. The in-hospital
mortality is signiﬁcant but the cumulative mortality at 6 months and 1
year is low, showed a good success rate of the P-PCI strategy. The
radial approach is feasible and safe. The invasive strategy in selected
very elderly population should be offered. Further studies are needed
to evaluate the beneﬁt of P-PCI versus non P-PCI strategy in the very
elderly population.
CATEGORIES CORONARY: Acute Myocardial Infarction
KEYWORDS Elderly, Primary percutaneous coronary intervention,
Radial
TCT-233
Prognostic value of left ventricular global function index in patients after
ST-segment elevation myocardial infarction
Sebastian Reinstadler,1 Hans-Josef Feistritzer,1 Bernhard Metzler1
1Innsbruck Medical University, Innsbruck, Austria
BACKGROUND The left ventricular global function index (LVGFI) is a
novel indicator of left ventricular performance. Its prognostic value in
patients after ST-segment elevation myocardial infarction (STEMI) is
unknown. We sought to evaluate the prognostic value of LVGFI
measured by cardiovascular magnetic resonance (CMR) imaging after
STEMI.
METHODS Two hundred eligible STEMI patients (5611 years, 16 %
female) revascularized by primary percutaneous coronary interven-
tion (PCI) were followed-up for 3.1 [2-4.1] years for major adverse
cardiac events (MACE). MACE was deﬁned as a composite of death,
nonfatal myocardial re-infarction and new congestive heart failure.
All patients underwent CMR imaging within 2 [2-4] days after STEMI.
Late enhancement and cine images were acquired to assess myocar-
dial injury as well as myocardial function, including LVGFI.
RESULTS Patients suffering a MACE event (n ¼ 20, 10%) had a
signiﬁcantly lower LVGFI (p ¼ 0.001). In Kaplan-Meier analysis, a
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(p ¼ 0.007). Multivariate Cox regression analysis revealed a decreased
LVGFI as an independent predictor for MACE (hazard ratio ¼ 5.24, 95
% CI 1.70-16.17, p ¼ 0.004) after adjusting for microvascular obstruc-
tion, multivessel disease and diabetes. In ROC analysis, LVGFI was a
strong predictor for MACE (AUC ¼ 0.73, CI 0.61-0.85). The predictive
value of LVEF was similar (AUC ¼ 0.74, CI 0.61-0.87).
CONCLUSIONS LVGFI assessed by CMR is a strong predictor of MACE
within 3 years after ﬁrst STEMI.
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BACKGROUND The pan-London PPCI network uses a 24/7 “Paramedic
Activated” service model with the London Ambulance Service (LAS)
across 8 Cardiac Centres - paramedics autonomously activate the PPCI
service from the community. This model aims to reduce ischemia time
by autonomous paramedic activation. Our Centre also serves a
catchment area surrounding London in which a “Cardiologist
Screened” service model is used in conjunction with the South East
Coast Ambulance Service (SECAMB) - paramedics telemetry link an
ECG to our Centre and discuss the case with the on-call Cardiologist. If
the case does not meet STEMI criteria, the SECAMB crew is redirected
to the nearest ED. This model intends to rationalize the number of
false activations in a catchment area with a much larger geographical
distribution (and therefore transfer times) than London. There are no
previous reports comparing a dual PPCI activation model within one
Centre. We compared the False Activation rates between our two
service models, as a metric of quality.
METHODS Over a 20-month period (January 2013 – August 2014) there
were 2077 consecutive activations of our PPCI service. Cases were
categorized by source of activation - Paramedic Activated (LAS) or
Cardiologist Screened (SECAMB, cardiac center ED or non-cardiac
center ED). Cases were also categorized as True Activations (STEMI
with PPCI or emergency CABG) or as False Activation (not STEMI, but
may have undergone emergency angiography).
RESULTS 942 (45.3%) cases were Paramedic Activated via LAS (LAS
Cohort) and 1038 (50.0%) cases were Cardiologist Screened via
SECAMB (SECAMB Cohort). 24 (1.2%) patients self presented to our ED
and 73 (3.5%) to local EDs – both were excluded from further analysis
for the purpose of comparing the two ambulance service models. The
proportion of False Activations was signiﬁcantly higher in the in the
SECAMB cohort compared to the LAS cohort: SECAMB 805 patients
(77.6%) and LAS 470 patients (49.9%); c2 164.8 (p<0.001). 708/1038 of
the SECAMB activations did not meet STEMI criteria were diverted to
local EDs. Of the SECAMB activations actually transferred to our
Centre (330 cases), the False Activation rate was signiﬁcantly lower
compared to the LAS Cohort: SECAMB 97 patients (29.4%) and LAS
470 patients (49.9%); c2 41.6 (p<0.001).LAS SECAMBCardiac
Centre EDNon-Cardiac
Centre EDTrue Activations 472 233 16 45False Activations 470 805 8 28Total Activations 942 1038 24 73False Activation
Rate49.9% 77.6% 33.3% 38.4%CONCLUSIONS On initial inspection our data does not support the
notion that a Cardiologist Screened service should have a lower False
Activation rate than a Paramedic Activated service. However once
diverted SECAMB referrals are excluded, the False Activation rate is
lower in the Cardiology Screened pathway. Our study highlights an
interesting portal to examine quality of PPCI activation service
models.
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BACKGROUND Poor R-wave progression (PRWP) on electrocardio-
grams has been reported to be associated with old myocardial
infarction (MI) due to an occlusion of the left anterior descending
(LAD) artery. However, PRWP can be observed in patients presenting
with acute MI who do not have history of MI. We hypothesized that
PRWP on admission electrocardiograms predict LAD culprit in our
cohort of patients with non-ST-segment Elevation Myocardial
Infarction (NSTEMI).
METHODS We performed a retrospective analysis of 481 consecutive
NSTEMI patients who underwent coronary angiography from January
2013 to June 2014. Patients with ventricular paced rhythm and bundle
branch block were excluded. In addition, patients with history of MI,
coronary artery bypass grafting, or heart failure were excluded.
Electrocardiograms on admission were interpreted in a blinded
fashion, and PRWP was deﬁned as a R-wave amplitude <3mm in lead
V3 on presenting electrocardiograms. Patients were divided into those
with and without PRWP. An independent cardiologist blinded to the
clinical data visually interpreted all coronary angiograms. LAD culprit
was deﬁned as LAD stenosis70% with either thrombus or ulcerative
base. Baseline and angiographic characteristics were recorded. In
addition, in-hospital heart failure, in-hospital and 30-day major
adverse cardiac events (MACE) including death, recurrent myocardial
infarction, ventricular ﬁbrillation, and target vessel revascularization
were recorded and compared between the two groups.
RESULTS Among 310 patients included in the ﬁnal analysis, 73 pa-
tients (23.5%) had PRWP. No statistically signiﬁcant difference was
observed in baseline characteristics between the two groups. Patients
with PRWP had a higher rate of Killip class>1 on admission than those
without (17.8% vs. 8.9%, p¼0.032). Although peak troponin I values
were comparable between the two groups (median [interquartile];
0.61 [0.15-3.38] ng/ml vs. 0.92 [0.13-6.47] ng/ml, p¼0.58), patients
with PRWP had a lower left ventricular ejection fraction than those
without (57 [39-60] % vs. 60 [55-65] %, p¼ 0.004). With respect to
angiographic ﬁnding, patients with PRWP had a higher rate of LAD
culprit than those without (35.6% vs. 23.2%, p¼0.035). The incidence
of in-hospital heart failure was higher in patients with PRWP than
those without (20.5% vs. 9.3%, p¼0.009). There was a trend toward a
higher incidence of in-hospital MACE (4.1% vs. 1.7%, p¼0.36) and 30-
day MACE (8.2% vs. 3.4%, p¼0.10) in patients with PRWP.
CONCLUSIONS In our cohort of patients with NSTEMI, PRWP on
admission electrocardiograms was associated with the presence of
LAD culprit. There was a trend toward a higher incidence of in-hos-
pital and 30-day MACE in patients with PRWP.
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BACKGROUND ADAMTS13 is a metalloprotease that cleaves von Wil-
lebrand factor (VWF), thereby reducing its prothrombotic properties.
There is considerable evidence that VWF levels increase and
ADAMTS13 levels decrease in STEMI patients. It is unclear if this
contributes to no reﬂow, infarct size and intramyocardial hemorrhage
(IMH). The aim of this study was to determine the role of ADAMTS13 in
patients with acute myocardial infarction; and to investigate the
beneﬁts of recombinant (r)ADAMTS13 in a porcine model of myocar-
dial ischemia-reperfusion with dual antiplatelet therapy and heparin.
METHODS In 49 consecutive PCI-treated STEMI patients, blood sam-
ples were collected directly after and up to 7 days following PCI.
